

Patient Treatments

Reference Number: F4853
Date of Response: 15/09/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- Benralizumab - **86 patients**
- Omalizumab - **88 patients**
- Reslizumab - **** patients**
- Mepolizumab - **25 patients**

**** - low value suppressed to protect patient identity. ≤5.**

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- Age 6-11 - **** patients**
- Age 12-17 - **7 patients**
- Age 18 and above - **189 patients**

**** - low value suppressed to protect patient identity**

Q3. How many patients have been treated in the last 4 months with Dupilumab for:

- Asthma ONLY - **17 Patients only treated for severe asthma.**
- Chronic rhinosinusitis with nasal polyps ONLY.
This question Is not applicable.

Q4. How many patients have been treated in the last 4 months with Omalizumab for:-

- Asthma ONLY **0 again we only use this for severe asthma only.**
Chronic rhinosinusitis with nasal polyps ONLY. **This question Is not applicable.**
- Chronic Spontaneous Urticaria ONLY. **This question Is not applicable.**